Australian’s Biotron Focuses On Developing Drug For Spreading Dengue
This article was originally published in PharmAsia News
Executive SummaryAustralian biotech Biotron and two universities are focusing on a drug to treat the dengue fever plaguing parts of the country. No drug or vaccine is available today to treat the disease and patients have to rely instead on treatments for the symptoms. The researchers are attempting to develop a drug that slows growth or at least inhibits the infection of the virus by binding with the proteins responsible. One of the scientists said the dengue virus is able to suppress some of the human's antiviral proteins, making it effective as a disease. (Click here for more
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.